These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1414555)

  • 21. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
    Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
    Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study.
    Maina G; Fiori L; Torta R; Fagiani MB; Ravizza L; Bonavita E; Ghiazza B; Teruzzi F; Zagnoni PG; Ferrario E
    Neuropsychobiology; 1989; 21(3):141-5. PubMed ID: 2693996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CNS pharmacology and clinical therapeutic effects of oxiracetam.
    Itil TM; Menon GN; Songar A; Itil KZ
    Clin Neuropharmacol; 1986; 9 Suppl 3():S70-2. PubMed ID: 3594458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia in comparison with a control group.
    Parnetti L; Mecocci P; Petrini A; Longo A; Buccolieri A; Senin U
    Neuropsychobiology; 1989; 22(2):97-100. PubMed ID: 2518332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selegiline versus oxiracetam in patients with Alzheimer-type dementia.
    Falsaperla A; Monici Preti PA; Oliani C
    Clin Ther; 1990; 12(5):376-84. PubMed ID: 2125242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
    Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial.
    Mori K; Inatomi S; Ouchi K; Azumi Y; Tuchida T
    Phytother Res; 2009 Mar; 23(3):367-72. PubMed ID: 18844328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study.
    Fagerlund B; Søholm B; Fink-Jensen A; Lublin H; Glenthøj BY
    Clin Neuropharmacol; 2007; 30(1):3-12. PubMed ID: 17272964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study.
    Schiff R; Bulpitt CJ; Wesnes KA; Rajkumar C
    Psychoneuroendocrinology; 2005 May; 30(4):309-15. PubMed ID: 15694110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
    Chiu CC; Su KP; Cheng TC; Liu HC; Chang CJ; Dewey ME; Stewart R; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1538-44. PubMed ID: 18573585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment trial of oxiracetam in Alzheimer's disease.
    Green RC; Goldstein FC; Auchus AP; Presley R; Clark WS; Van Tuyl L; Green J; Hersch SM; Karp HR
    Arch Neurol; 1992 Nov; 49(11):1135-6. PubMed ID: 1444879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy.
    Aldenkamp AP; van Wieringen A; Alpherts WC; van Emde Boas W; Haverkort HA; de Vries J; Meinardi H
    Neuropsychobiology; 1990-1991; 24(2):90-101. PubMed ID: 2134116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?
    Gainotti G; Nocentini U; Sena E
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13 Suppl():S47-59. PubMed ID: 2694229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life.
    Saletu B; Linzmayer L; Grünberger J; Pietschmann H
    Neuropsychobiology; 1985; 13(1-2):44-52. PubMed ID: 3897895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Organic brain syndrome treated with oxiracetam. A double-blind randomized controlled trial.
    Hjorther A; Browne E; Jakobsen K; Viskum P; Gyntelberg F
    Acta Neurol Scand; 1987 Apr; 75(4):271-6. PubMed ID: 3296624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.
    Gillis JC; Benefield P; McTavish D
    Drugs Aging; 1994 Aug; 5(2):133-52. PubMed ID: 7981485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxiracetam in the treatment of multi-infarct dementia.
    Baumel B; Eisner L; Karukin M; MacNamara R; Katz RJ; Deveaugh-Geiss J
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(5):673-82. PubMed ID: 2781039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial.
    Lim JS; Lee J; Kang Y; Park HT; Kim DE; Cha JK; Park TH; Heo JH; Lee KB; Park JM; Oh MS; Kim EG; Chang DI; Heo SH; Park MS; Park H; Yi S; Lee YB; Park KY; Lee SJ; Kim JG; Lee J; Cho KH; Rha JH; Kim YI; Lee JH; Choi JC; Oh KM; Kwon JH; Kim C; Park JH; Jung KH; Sung SM; Chung JW; Lee YS; Kim HY; Cho HJ; Park JW; Moon WJ; Bae HJ
    Contemp Clin Trials; 2023 Mar; 126():107108. PubMed ID: 36724841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.